Peripheral Neuropathy (Sensory Neuropathy) ' Pipeline Review, H2 2012

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

Peripheral Neuropathy (Sensory Neuropathy) ' Pipeline Review, H2
2012
Published on September 2012

Report Summary

Peripheral Neuropathy (Sensory Neuropathy) ' Pipeline Review, H2 2012

Summary

Global Markets Direct's, 'Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2012', provides an overview of the
indication's therapeutic pipeline. This report provides information on the therapeutic development for Peripheral Neuropathy (Sensory
Neuropathy), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players
involved in the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy). Peripheral Neuropathy (Sensory
Neuropathy) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary
databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university
sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated
disease.

Scope

- A snapshot of the global therapeutic scenario for Peripheral Neuropathy (Sensory Neuropathy).
- A review of the Peripheral Neuropathy (Sensory Neuropathy) products under development by companies and universities/research
institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Peripheral Neuropathy (Sensory Neuropathy) pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Peripheral Neuropathy (Sensory
Neuropathy).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive
advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Peripheral Neuropathy (Sensory Neuropathy) pipeline depth and
focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Peripheral Neuropathy (Sensory Neuropathy) ' Pipeline Review, H2 2012 (From Slideshare) Page 1/6


Table of Content

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Peripheral Neuropathy (Sensory Neuropathy) Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Peripheral Neuropathy (Sensory Neuropathy) 8
Peripheral Neuropathy (Sensory Neuropathy) Therapeutics under Development by Companies 10
Peripheral Neuropathy (Sensory Neuropathy) Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Discovery and Pre-Clinical Stage Products 15
Peripheral Neuropathy (Sensory Neuropathy) Therapeutics ' Products under Development by Companies 16
Peripheral Neuropathy (Sensory Neuropathy) Therapeutics ' Products under Investigation by Universities/Institutes 17
Companies Involved in Peripheral Neuropathy (Sensory Neuropathy) Therapeutics Development 18
NsGene A/S 18
Neuren Pharmaceuticals Limited 19
NeurogesX, Inc. 20
Allon Therapeutics Inc. 21
Peripheral Neuropathy (Sensory Neuropathy) ' Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Combination Products 23
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
capsaicin - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
AL-309 - Drug Profile 29
R&D Progress 29
NNZ-2591 - Drug Profile 30
R&D Progress 30
NsG-31 - Drug Profile 32



R&D Progress 32
amifostine - Drug Profile 33
R&D Progress 33
Amitriptyline + Ketamine - Drug Profile 34
R&D Progress 34
glutamine - Drug Profile 35
R&D Progress 35
Carboplatin + Glutathione + Paclitaxel - Drug Profile 36
R&D Progress 36
thioctic acid [JAN] - Drug Profile 38
R&D Progress 38
Immunoglobulin - Drug Profile 39
R&D Progress 39
flupirtine maleate - Drug Profile 40
R&D Progress 40
Peripheral Neuropathy (Sensory Neuropathy) Therapeutics ' Drug Profile Updates 41
Peripheral Neuropathy (Sensory Neuropathy) Therapeutics ' Discontinued Products 43
Peripheral Neuropathy (Sensory Neuropathy) Therapeutics - Dormant Products 44
Peripheral Neuropathy (Sensory Neuropathy) ' Product Development Milestones 45
Featured News & Press Releases 45
Nov 17, 2011: Pfizer Obtains European Approval For Vyndaqel For Transthyretin Familial Amyloid Polyneuropathy 45
Feb 09, 2011: CeNeRx Receives FDA IND Approval For CXB909 46
Feb 07, 2011: EpiCept Reports Positive Results From EpiCept NP-1 Trial In Patients With Chemotherapy-Induced Peripheral
Neuropathy 47
Sep 08, 2010: DARA Announces Phase III Trial Results Of KRN5500 In Patients With Chemotherapy Induced Peripheral Neuropathy
And Advanced Cancer 48
Jun 11, 2010: Pfizer, Eisai to launch postherpetic neuralgia drug Lyrica Capsules on June 22 48
Jun 11, 2010: Pfizer, Eisai to launch postherpetic neuralgia drug Lyrica Capsules on June 22 48
May 28, 2010: Relevare Pharmaceuticals Presents Latest Clinical Trial Data On CNSB015 At Third International Congress On
Neuropathic Pain In Athens, Greece 49
Apr 06, 2010: Pfizer told to Pay $142.1 million for Neurontin marketing violations. 49
Dec 20, 2009: CNSBio Inc. To Present Latest Clinical Trial Data For CNSB015 At Neuropathic Pain Conference in San Francisco 50
Nov 18, 2009: NeoPharm Presents LE-DT Phase I Data At The AACR Conference 50



Appendix 51
Methodology 51
Coverage 51
Secondary Research 51
Primary Research 51
Expert Panel Validation 51
Contact Us 52
Disclaimer 52

List of Tables

Number of Products Under Development for Peripheral Neuropathy (Sensory Neuropathy), H2 2012 8
Products under Development for Peripheral Neuropathy (Sensory Neuropathy) ' Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 10
Number of Products under Investigation by Universities/Institutes, H2 2012 12
Comparative Analysis by Late Stage Development, H2 2012 13
Comparative Analysis by Mid Clinical Stage Development, H2 2012 14
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 15
Products under Development by Companies, H2 2012 16
Products under Investigation by Universities/Institutes, H2 2012 17
NsGene A/S, H2 2012 18
Neuren Pharmaceuticals Limited, H2 2012 19
NeurogesX, Inc., H2 2012 20
Allon Therapeutics Inc., H2 2012 21
Assessment by Monotherapy Products, H2 2012 22
Assessment by Combination Products, H2 2012 23
Assessment by Stage and Route of Administration, H2 2012 25
Assessment by Stage and Molecule Type, H2 2012 27
Peripheral Neuropathy (Sensory Neuropathy) Therapeutics ' Drug Profile Updates 41
Peripheral Neuropathy (Sensory Neuropathy) Therapeutics ' Discontinued Products 43
Peripheral Neuropathy (Sensory Neuropathy) Therapeutics ' Dormant Products 44

List of Figures

Number of Products under Development for Peripheral Neuropathy (Sensory Neuropathy), H2 2012 8
Products under Development for Peripheral Neuropathy (Sensory Neuropathy) ' Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 11
Late Stage Products, H2 2012 13
Mid Clinical Stage Products, H2 2012 14
Discovery and Pre-Clinical Stage Products, H2 2012 15
Assessment by Monotherapy Products, H2 2012 22
Assessment by Combination Products, H2 2012 23
Assessment by Route of Administration, H2 2012 24
Assessment by Stage and Route of Administration, H2 2012 25
Assessment by Molecule Type, H2 2012 26
Assessment by Stage and Molecule Type, H2 2012 27


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.

Peripheral Neuropathy (Sensory Neuropathy) ' Pipeline Review, H2 2012

Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 2 000.00 Quantity: _____

Site License--USD 4 000.00 Quantity: _____

Corporate License--USD 6 000.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


Peripheral Neuropathy (Sensory Neuropathy) ' Pipeline Review, H2 2012

Recommended

Recommended

More Related Content

More from ReportLinker.com

More from ReportLinker.com (20)

Peripheral Neuropathy (Sensory Neuropathy) ' Pipeline Review, H2 2012